FilingsTodayInnogene
At a glance
Innogene filed 45 disclosures in the last 12 months, including 5 5% holder, 4 insider, 2 buyback, 2 issuance and 1 contract. The most recent key filing was on Sep 22: A major holder's stake fell from 8.09% to 5.68%.
Revenue for 2025 was ₩8.2B, down 8.2% on 2024. Operating margin was 0.1% against 7% a year earlier. Debt was 7% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩7.4B and operating loss of ₩705.9M.
The 2025 annual report lists 58 employees with an average tenure of 2.9 years and average pay of ₩40.8M, #2065 of 2,191 listed companies by average pay. Its 5 directors and auditors were paid ₩121M each on average. It paid ₩90 per common share in cash dividends, against ₩80 a year earlier (+12.5%). 이광훈 and related parties held 36.40% at year end.
Of 5 recent 5%+ holder reports, 3 raised and 2 cut a stake; the largest stake reported was 49.09% on Aug 24.
From the 2025 annual report
Staff: 58 (20 men, 38 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩2.4B. Directors and auditors: 5, paid ₩609M in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩90 | ₩80 | ₩30 |
| Payout ratio | 342% | 101.2% | 25.7% |
| Yield (as filed) | 4.50% | 5.30% | 1.10% |
| Total cash dividends | ₩985M | ₩957M | ₩359M |
Largest shareholder
이광훈 holds 34.50%; with 1 related party the group holds 36.40% of common shares at year end.
Auditor: 삼정회계법인 · opinion: Unqualified.
Source: 2025 annual business report (DART). How figures are combined
New contracts, last 12 months
1 new supply contract worth 5% of the revenue stated in the filings.
Amended amounts replace the originals. Subsidiary contracts and terminations are excluded.
Financial summary
5%+ holder reports
Key filings
Other filings
Links open the original filing on DART, in Korean.